Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: protocol of the multicentre, open-label, phase II, INTERACT-II trial.
van de Vlasakker VCJ, Guchelaar NAD, van den Heuvel TBM, Lurvink RJ, van Meerten E, Bax RJF, Creemers GM, van Hellemond IEG, Brandt-Kerkhof ARM, Madsen EVE, Nederend J, Koolen SLW, Nienhuijs SW, Kranenburg O, de Hingh IHJT, Verhoef C, Mathijssen RHJ, Burger JWA; Dutch Peritoneal Oncology Group; Dutch Colorectal Cancer Group.
van de Vlasakker VCJ, et al. Among authors: de hingh ihjt.
BMJ Open. 2024 Jan 18;14(1):e077667. doi: 10.1136/bmjopen-2023-077667.
BMJ Open. 2024.
PMID: 38238055
Free PMC article.